Condensed Statements of Shareholders' Deficiency - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)			1,233,853
Beginning balance	$ (1,090,604)	$ (979,147)	$ (1,034,012)	$ (930,624)
Net loss	$ (28,906)	(22,697)	$ (85,498)	(71,220)
Ending balance (in shares)	1,233,853		1,233,853
Ending balance	$ (1,119,510)	$ (1,001,844)	$ (1,119,510)	$ (1,001,844)
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	1,233,853	1,233,853	1,233,853	1,233,853
Beginning balance	$ 1,233	$ 1,233	$ 1,233	$ 1,233
Ending balance (in shares)	1,233,853	1,233,853	1,233,853	1,233,853
Ending balance	$ 1,233	$ 1,233	$ 1,233	$ 1,233
Additional Paid-in Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	81,323	81,323	81,323	81,323
Ending balance	81,323	81,323	81,323	81,323
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(1,173,160)	(1,061,703)	(1,116,568)	(1,013,180)
Net loss	(28,906)	(22,697)	(85,498)	(71,220)
Ending balance	$ (1,202,066)	$ (1,084,400)	$ (1,202,066)	$ (1,084,400)